A Blinded Randomized Parallel Trial to Define the ECG Effects of Bardoxolone Methyl Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Bardoxolone methyl (Primary) ; Moxifloxacin
- Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Haematological malignancies; Intra-abdominal infections; Malignant melanoma; Pancreatic cancer; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Solid tumours; Tuberculosis
- Focus Pharmacodynamics
- Sponsors Biogen; Reata Pharmaceuticals
- 16 Apr 2013 New trial record